R-MPV (Rituximab + HD-Methotrexate + Procarbazine + Vincristine), 5 cycles q14d
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-RITUXIMAB DRUG-METHOTREXATE DRUG-VINCRISTINE DRUG-PROCARBAZINE |
|---|
| ID | REG-R-MPV |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Notes
STUB. MSKCC standard induction (Morris 2013). Default for the Ukrainian context when thiotepa is unavailable. Vincristine — NEVER intrathecally (fatal). MAOI dietary restrictions while on procarbazine.
Used By
Contraindications
CI-RENAL-FAILURE-FOR-HD-MTX- CI-RENAL-FAILURE-FOR-HD-MTX
Indication
IND-PCNSL-1L-R-MPV- IND-PCNSL-1L-R-MPV